Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3331-3335

  Choi, Joon Hyuk ^a   Kim, Tae Nyeun ^a   Kim, Seongyong ^a   Baek, Suk Hwan ^a   Kim, Jung Hye ^a   Lee, Seung Rock ^b   Kim, Jae Ryong ^a  

^a Yeungnam University College of Medicine   (South Korea)

^b Ewha Womans University   (South Korea)

Author keywords

Hepatocellular carcinoma; Immunohistochemistry; Mitochondrial thioredoxin reductase; Peroxiredoxin III

Indexed keywords

HYDROGEN PEROXIDE; MITOCHONDRIAL ENZYME; PEROXIREDOXIN; PEROXIREDOXIN III; THIOREDOXIN II; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL DEATH; CELL RESPIRATION; CONTROLLED STUDY; ENZYME LOCALIZATION; FEMALE; HUMAN; LIVER CELL CARCINOMA; MALE; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOCHONDRIA; PEROXIDASES; THIOREDOXIN REDUCTASE (NADPH);

EID: 0036870093     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kovacic P and Jacintho JD: Mechanisms of carcinogenesis: focus on oxidative stress and electron transfer. Curr Med Chem 8: 773-796, 2001.
2. Kamata H and Hirata H: Redox regulation of cellular signalling. Cell Signal 11: 1-14, 1999.
3. Jackson AL and Loeb LA: The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat Res 477: 7-21, 2001.
4. Chevion M, Berenshtein E and Stadtman ER: Human studies related to protein oxidation: protein carbonyl content as a marker of damage. Free Radic Res 33 Suppl: S99-S108, 2000.
5. Klaunig JE, Xu Y, Isenberg JS, Backowski S, Kolaja KL, Jiang J, Stevenson DE and Walborg EF Jr: The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect 106 Suppl 1: 289-295, 1998.
6. Thannickal VJ and Fanburg BL: Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279: L1005-L1028, 2000.
7. Powis G, Briehl M and Oblong J: Redox signalling and the control of cell growth and death. Pharmacol Ther 68: 149-173, 1995.
8. Arner ES and Holmgren A: Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267: 6102-6109, 2000.
9. Powis G and Montfort WR: Properties and biological activities of thioredoxins. Annu Rev Pharmacol Toxicol 41: 261-295, 2001.
10. Pedrajas JR, Kosmidou E, Miranda-Vizuete A, Gustafsson JA, Wright AP and Spyrou G: Indentification and functional characterization of a novel mitochondrial thioredoxin system in Saccharomyces cerevisiae. J Biol Chem 274: 6366-6373, 1999.
11. Lee SR, Kim JR, Kwon KS, Yoon HW, Levine RL, Ginsburg A and Rhee SG: Molecular cloning and characterization of a mitochondrial selenocysteine-containing thioredoxin reductase from rat liver. J Biol Chem 274: 4722-4734, 1999.
12. Lee SR, Bar-Noy S, Kwon J, Levine RL, Stadtman TC and Rhee SG: Mammalian thioredoxin reductase: oxidation of the C-terminal cysteine/selenocysteine active site forms a thioselenide, and replacement of selenium with sulfur markedly reduces catalytic activity. Proc Natl Acad Sci USA 97: 2521-2526, 2000.
13. Zhong L, Arner ES and Holmgren A: Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci USA 97: 5854-5859, 2000,
14. Chae HZ, Chung SJ and Rhee SG: Thioredoxin-dependent peroxide reductase from yeast. J Biol Chem 269: 27670-27678, 1994.
15. Rhee SG, Kang SW, Netto LE, Seo MS and Stadtman ER: A family of novel peroxidases, peroxiredoxins. Biofactors 10: 207-209, 1999.
16. Chae HZ, Robison K, Poole LB, Church G, Storz G and Rhee SG: Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA 91: 7017-7021, 1994.
17. Berggren M, Gallegos A, Gasdaska JR, Gasdaska PY, Warneke J and Powis G: Thioredoxin and thioredoxin reductase gene expression in human tumors and cell lines, and the effects of serum stimulation and hypoxia. Anticancer Res 16: 3459-3466, 1996.
18. Baker A, Payne CM, Briehl MM and Powis G: Thioredoxin, a gene found overexpressed in human cancer, inhibits apoptosis in vitro and in vivo. Cancer Res 57: 5162-5167, 1997.
19. Grogan TM, Fenoglio-Prieser C, Zeheb R, Bellamy W, Frutiger Y, Vela E, Stemmerman G, Macdonald J, Richter L, Gallegos A and Powis G: Thioredoxin, a putative oncogene product, is overexpressed in gastric carcinoma and associated with increased proliferation and increased cell survival. Hum Pathol 31: 475-481, 2000.
20. Soini Y, Kahlos K Napankangas U, Kaarteenaho-Wiik R, Saily M, Koistinen P, Paaakko P, Holmgren A and Kinnula VL: Widespread expression of thioredoxin and thioredoxin reductase in non-small cell lung carcinoma. Clin Cancer Res 7: 1750-1757, 2001.
21. Nakamura H, Masutani H, Tagaya Y, Yamauchi A, Inamoto T, Nanbu Y, Fujii S, Ozawa K and Yodoi J: Expression and growth-promoting effect of adult T-cell leukemia-derived factor. A human thioredoxin homologue in hepatocellular carcinoma. Cancer 69: 2091-2097, 1992.
22. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
23. Yanagawa T, Iwasa S, Ishii T, Tabuchi K, Yusa H, Onizawa K, Omura K, Harada H, Suzuki H and Yoshida H: Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett 156: 27-35, 2000.
24. Yanagowa T, Ishikawa T, Ishii T, Tabuchi K, Iwasa S, Bannai S, Omura K, Suzuki H and Yoshida H: Peroxiredoxin I expression in human thyroid tumors. Cancer Lett 145: 127-132, 1999.
25. Kawahara N, Tanaka T, Yokomizo A, Nanri H, Ono M, Wada M, Kohno K, Takenaka K, Sugimachi K and Kuwano M: Enhanced coexpression of thioredoxin and high mobility group protein 1 genes in human hepatocellular carcinoma and the possible association with decreased sensitivity to cisplatin. Cancer Res 56: 5330-5333, 1996.